Categories AlphaGraphs, Earnings, Health Care
Earnings: Highlights of Eli Lilly & Company’s (LLY) Q1 2023 results
Eli Lilly and Company (NYSE: LLY) on Thursday reported lower earnings and revenues for the first quarter of 2023. The company also provided guidance for fiscal 2023.
The Indianapolis-based pharmaceutical company said its revenues declined 11% year-over-year to $6.96 billion in the first quarter, hurt by lower realized prices and a decline in volumes.
The weak top-line performance translated into a 38% fall in net earnings, on an adjusted basis, to $1.62 per share. Unadjusted profit decreased to $1.34 billion or $1.49 per share from $1.90 billion or $2.10 per share in the first quarter of 2022.
“Core business growth drove solid first-quarter financial results and a strong start for Lilly in 2023, which includes pipeline progress led by positive SURMOUNT-2 data for tirzepatide in obesity,” said David Ricks, CEO of Eli Lilly.
Prior Performance
Most Popular
StubHub Holdings set to enter public markets. Here’s what to expect
After a modest start to the year, the IPO market is witnessing an increase in activity led by technology and healthcare companies. StubHub Holdings, a leading online ticket marketplace for
Can Beyond Meat (BYND) overcome its persistent challenges?
Shares of Beyond Meat, Inc. (NASDAQ: BYND) stayed red on Tuesday. The stock has dropped 19% over the past three months. The plant-based meat company continues to struggle in terms
CarMax (KMX) likely to report strong earnings growth for Q4 2025
After reporting robust earnings growth for the third quarter, CarMax, Inc. (NYSE: KMX) is preparing to publish Q4 results next week. Over the years, the company has fostered customer loyalty
